Browse Articles

Acquired immunodeficiency syndrome (AIDS) is a life-threatening condition caused by the human immunodeficiency virus (HIV). In this work, Takemaru et al explored the role of Coiled-Coil Domain-Containing 11 (CCDC11) in HIV-1 budding. Their results suggest that CCDC11 is critical for efficient HIV-1 budding, potentially indicating CCDC11 a viable target for antiviral therapeutics without major side effects.

Phage therapy has been suggested as an alternative to antibiotics because bacteria resistant to antibiotics may still be susceptible to phages. However, phages may have limited effectiveness in combating bacteria since bacteria possess several antiviral defense mechanisms and can quickly develop resistance to phages. In this study, Wu and Pinta compare the effectiveness and specificity of antibiotics and phages in combating bacteria. They found that T4 phages are more specific and effective in fighting or inhibiting both antibiotic-resistant and sensitive bacteria than antibiotics, suggesting that phage therapy can be developed as an efficient tool to combat antibiotic-resistant bacteria.

Human cytomegalovirus (HCMV) causes serious infections in immunocompromised patients and therapies to inhibit latent HCMV are not developed. Using CRISPR/Cas9, the authors were able to delete an important promoter region in HCMV.

Human immunodeficiency virus (HIV), which affects tens of millions of individuals worldwide, can lead to acquired immunodeficiency syndrome (AIDS). While there is currently no cure for HIV, the development of small molecule antiretroviral agents has greatly improved the prognosis of infected individuals, especially in developed countries. Here, the authors employ homology modeling and molecular docking towards the identification of novel rilpivirine analogs that retain high binding affinity to clinically relevant rilpivirine-resistant mutations of the HIV reverse transcriptase enzyme.